+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Swine Epidemic Encephalitis Inactivated Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Swine Epidemic Encephalitis Inactivated Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Swine Epidemic Encephalitis Inactivated Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082031
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The swine epidemic encephalitis inactivated vaccine market stands at a critical juncture, driven by heightened biosecurity concerns and a growing emphasis on animal health. As swine producers worldwide grapple with viral threats that can decimate herds and disrupt global pork supply, inactivated vaccine platforms have emerged as a reliable defense. Regulatory agencies are tightening standards, pushing manufacturers to adopt rigorous safety and efficacy protocols. Meanwhile, technological advances-from refined adjuvant formulations to scalable production technologies-are expanding the toolkit available to developers.

Innovation in vaccine development is converging with strategic shifts in industry structure. Established players are investing in recombinant DNA and viral vector platforms to enhance immunogenicity, while smaller specialists explore nano-particle adjuvants to boost potency. Supply chain resilience has become paramount as recent disruptions exposed vulnerabilities in raw material sourcing. At the same time, end users-farm owners, veterinary hospitals and pharmaceutical companies-are seeking integrated solutions that offer predictable performance and seamless logistics. In this evolving ecosystem, stakeholders must navigate complex regulatory pathways, respond to shifting trade policies, and leverage emerging technologies to protect swine populations effectively.

Transformative Shifts Redefining the Vaccine Landscape

The landscape of swine epidemic encephalitis inactivated vaccines is undergoing transformative shifts fueled by scientific breakthroughs and evolving market demands. Gene-based platforms such as RNA vaccines, once confined to human therapeutics, are now accelerating preclinical pipelines in animal health. Concurrently, traditional production methods are being augmented by advanced recombinant DNA technology and cell culture systems-enhancing yield, consistency and safety profiles. This fusion of legacy and cutting-edge approaches is reshaping how developers prioritize speed to market without compromising on regulatory compliance.

Digitalization is playing a catalytic role: predictive analytics streamline batch release, while blockchain solutions fortify cold-chain integrity. At the same time, a strategic push toward One Health frameworks is fostering collaboration between veterinary institutes and human health authorities to monitor zoonotic spillover risks. Consolidation among contract manufacturers and collaborations between academic research institutes and industry players are further expanding capacity, ensuring that vaccine developers can meet surging demand even as they adhere to stringent quality standards. In parallel, rising consumer awareness around animal welfare and food safety is prompting stakeholders to adopt transparent communication strategies-reinforcing confidence in immunization programs and laying the groundwork for sustainable growth.

Navigating US Tariffs: Supply Chain Reconfiguration in 2025

The cumulative impact of United States tariffs in 2025 has reverberated across the swine vaccine supply chain, altering cost structures and procurement strategies. Increased duties on imported adjuvant raw materials compelled manufacturers to diversify sourcing toward domestic cell culture reagents, while tariffs on specialized fermentation equipment accelerated investments in onshore production facilities. This reconfiguration has led to marginally higher production costs, which in turn have influenced pricing negotiations with veterinary clinics, pharmaceutical stores and online pharmacies.

To mitigate these headwinds, several developers have entered into strategic partnerships with domestic suppliers of viral vector-based technology and nano-particle adjuvants, securing more predictable lead times and cost stability. At the regulatory level, agencies have responded by fast-tracking certification processes for local suppliers to alleviate bottlenecks. Meanwhile, end users such as farm owners and veterinary hospitals have adapted procurement cycles, shifting toward bulk purchasing agreements and long-term supply contracts. Ultimately, the tariff environment has driven a push for supply chain resilience and local capacity building, transforming what was once a largely globalized framework into a more regionally focused ecosystem.

In-Depth Segmentation Insights for Targeted Strategy

Deep analysis of market segmentation reveals nuanced opportunities across multiple axes. Based on Type, developers find that while DNA vaccines and inactivated whole virus vaccines remain foundational, live attenuated vaccines and protein subunit vaccines are gaining traction due to their enhanced safety profiles; at the same time, RNA vaccines are emerging as a disruptive force with potential for rapid iteration. Segmentation by Application underscores veterinary use as the primary driver, though research use and commercial use carve out distinct niches, especially within academic and pharmaceutical laboratories. Distribution Channels analysis highlights a shift toward veterinary clinics as trusted points of care, even as online pharmacies and pharmaceutical stores continue to serve remote and urban farming communities.

End Users range from farm owners prioritizing cost-effective, scalable solutions to research institutes demanding cutting-edge adjuvant systems such as nano-particle adjuvants and oil-in-water emulsions. When considering Animal Type, swine represent the core focus, though vaccine developers maintain capabilities to address ruminant applications. Production Technology segmentation shows that cell culture systems and viral vector-based approaches are attracting significant investment alongside traditional production methods. Dosage Form preferences skew toward lyophilized powder for its stability, while liquid formulations and suspensions serve targeted vaccination campaigns. Age Group insights reveal piglets as a critical cohort for early intervention, supported by formulations tailored to juvenile swine and adult swine. Disease Indication remains centered on classical swine fever and encephalitis, with growing attention on porcine reproductive and respiratory syndrome. Efficacy Duration considerations favor long-term immunity platforms, and Production Scale analysis indicates that large-scale production capacity is becoming a key competitive differentiator.

Key Regional Dynamics Shaping Market Priorities

Regional dynamics are shaping the swine epidemic encephalitis vaccine market in distinct ways across the globe. In the Americas, robust infrastructure, established regulatory pathways and mature cold-chain logistics underpin a stable commercial environment; manufacturers here are exploring advanced recombinant DNA technology and partnerships with veterinary hospitals to fine-tune distribution efficiency. Meanwhile, Europe, Middle East & Africa present a mosaic of regulatory landscapes: European nations emphasize rigorous safety standards, Middle Eastern markets prioritize rapid capacity expansion, and African regions focus on affordability and disease surveillance, driving innovation in cost-effective formulations such as lyophilized powder. In the Asia-Pacific region-characterized by the world’s largest swine populations-rapid urbanization and rising protein consumption fuel demand for scalable solutions, prompting the adoption of nano-particle adjuvants and cell culture systems to boost immunogenicity and streamline manufacturing footprints.

Competitive Landscape and Key Player Strategies

Leading industry participants are advancing specialized portfolios and forging strategic alliances to secure market leadership. Baader Solutions leverages its precision cell culture platforms to enhance production yields, while Biovac focuses on cost-efficient manufacturing to support large-scale deployment. Boehringer Ingelheim Animal Health and Ceva Santé Animale emphasize integrated vaccines that address multiple disease indications in a single regimen. Elanco Animal Health Incorporated and Zoetis Inc. invest heavily in RNA vaccine research, seeking to accelerate trial timelines. Hester Biosciences Limited and Indian Immunologicals Limited capitalize on established regional networks to expand reach, and HIPRA collaborates with research institutes to refine adjuvant systems. IDT Biologika and Phibro Animal Health Corporation are strengthening supply chains through localized production hubs, while Merck Animal Health and MSD Animal Health pursue strategic acquisitions to broaden technology portfolios. Romvac and the VIRBAC Group differentiate via targeted dosage forms and tailored age group formulations, ensuring comprehensive coverage from piglets to adult swine.

Actionable Recommendations for Industry Leadership

Industry leaders can harness several actionable strategies to navigate the evolving vaccine ecosystem effectively. First, prioritize investment in platform technologies-such as RNA and viral vector-based systems-that enable rapid response to emerging viral strains while ensuring long-term immunity. Second, reinforce supply chain resilience by establishing local sourcing partnerships for cell culture reagents and nano-particle adjuvants, mitigating exposure to geopolitical shifts like tariffs. Third, expand distribution footprints through digital channels and strategic alliances with veterinary clinics, pharmaceutical stores and online pharmacies to enhance reach among farm owners and veterinary hospitals.

Fourth, tailor product portfolios to address specific age groups and disease indications, emphasizing formulations optimized for piglets, juvenile swine and adult swine to capture critical intervention windows. Fifth, cultivate robust regulatory engagement to expedite approvals for advanced recombinant DNA vaccines and novel adjuvant combinations such as oil-in-water emulsions. Lastly, leverage data analytics and blockchain-enabled cold-chain tracking to bolster transparency, support compliance and strengthen customer confidence.

Conclusion and Strategic Imperatives

The swine epidemic encephalitis inactivated vaccine sector is poised for sustained innovation, propelled by advanced technologies and shifting market demands. Stakeholders who integrate cutting-edge production methods with resilient supply chain strategies will command competitive advantage. By aligning portfolios with nuanced segmentation insights-spanning vaccine types, applications, dosage forms and target age groups-developers can address the precise needs of farm owners, veterinary hospitals and research institutes.

The regional mosaic of regulatory rigor, infrastructure maturity and disease prevalence underscores the importance of adaptive approaches across the Americas, Europe, Middle East & Africa and Asia-Pacific. Strategic collaborations, rigorous regulatory engagement and transparent communications will remain essential as the market navigates tariff-driven headwinds and evolving biosecurity imperatives. Ultimately, a steadfast commitment to innovation, quality and stakeholder alignment will define market leadership in the swine epidemic encephalitis vaccine arena.

Market Segmentation & Coverage

This research report categorizes the Swine Epidemic Encephalitis Inactivated Vaccine Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • DNA Vaccines
  • Inactivated Whole Virus Vaccines
  • Live Attenuated Vaccines
  • Protein Subunit Vaccines
  • RNA Vaccines
  • Commercial Use
  • Research Use
  • Veterinary Use
  • Online Pharmacies
  • Pharmaceutical Stores
  • Veterinary Clinics
  • Farm Owners
  • Pharmaceutical Companies
  • Research Institutes
  • Veterinary Hospitals
  • Ruminants
  • Swine
  • Advanced Recombinant DNA Technology
  • Cell Culture Systems
  • Traditional Production Methods
  • Viral Vector-based Technology
  • Liquid Formulations
  • Lyophilized Powder
  • Suspensions
  • Adult Swine
  • Juvenile Swine
  • Piglets
  • Nano-Particle Adjuvants
  • Oil-in-Water Emulsions
  • Water-in-Oil Emulsions
  • Classical Swine Fever
  • Encephalitis
  • Porcine Reproductive and Respiratory Syndrome
  • Long-term Immunity
  • Short-term Immunity
  • Large-scale Production
  • Medium-scale Production
  • Small-scale Production

This research report categorizes the Swine Epidemic Encephalitis Inactivated Vaccine Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Swine Epidemic Encephalitis Inactivated Vaccine Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Baader Solutions
  • Biovac
  • Boehringer Ingelheim Animal Health
  • Ceva Santé Animale
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • HIPRA
  • IDT Biologika
  • Indian Immunologicals Limited
  • Merck Animal Health
  • MSD Animal Health
  • Phibro Animal Health Corporation
  • Romvac
  • VIRBAC Group
  • Zoetis Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Type
8.1. Introduction
8.2. DNA Vaccines
8.3. Inactivated Whole Virus Vaccines
8.4. Live Attenuated Vaccines
8.5. Protein Subunit Vaccines
8.6. RNA Vaccines
9. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Application
9.1. Introduction
9.2. Commercial Use
9.3. Research Use
9.4. Veterinary Use
10. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Distribution Channels
10.1. Introduction
10.2. Online Pharmacies
10.3. Pharmaceutical Stores
10.4. Veterinary Clinics
11. Swine Epidemic Encephalitis Inactivated Vaccine Market, by End Users
11.1. Introduction
11.2. Farm Owners
11.3. Pharmaceutical Companies
11.4. Research Institutes
11.5. Veterinary Hospitals
12. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Animal Type
12.1. Introduction
12.2. Ruminants
12.3. Swine
13. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Production Technology
13.1. Introduction
13.2. Advanced Recombinant DNA Technology
13.3. Cell Culture Systems
13.4. Traditional Production Methods
13.5. Viral Vector-based Technology
14. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Dosage Form
14.1. Introduction
14.2. Liquid Formulations
14.3. Lyophilized Powder
14.4. Suspensions
15. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Age Group of Target Animal
15.1. Introduction
15.2. Adult Swine
15.3. Juvenile Swine
15.4. Piglets
16. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Adjuvant Type
16.1. Introduction
16.2. Nano-Particle Adjuvants
16.3. Oil-in-Water Emulsions
16.4. Water-in-Oil Emulsions
17. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Disease Indication
17.1. Introduction
17.2. Classical Swine Fever
17.3. Encephalitis
17.4. Porcine Reproductive and Respiratory Syndrome
18. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Efficacy Duration
18.1. Introduction
18.2. Long-term Immunity
18.3. Short-term Immunity
19. Swine Epidemic Encephalitis Inactivated Vaccine Market, by Production Scale
19.1. Introduction
19.2. Large-scale Production
19.3. Medium-scale Production
19.4. Small-scale Production
20. Americas Swine Epidemic Encephalitis Inactivated Vaccine Market
20.1. Introduction
20.2. Argentina
20.3. Brazil
20.4. Canada
20.5. Mexico
20.6. United States
21. Asia-Pacific Swine Epidemic Encephalitis Inactivated Vaccine Market
21.1. Introduction
21.2. Australia
21.3. China
21.4. India
21.5. Indonesia
21.6. Japan
21.7. Malaysia
21.8. Philippines
21.9. Singapore
21.10. South Korea
21.11. Taiwan
21.12. Thailand
21.13. Vietnam
22. Europe, Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine Market
22.1. Introduction
22.2. Denmark
22.3. Egypt
22.4. Finland
22.5. France
22.6. Germany
22.7. Israel
22.8. Italy
22.9. Netherlands
22.10. Nigeria
22.11. Norway
22.12. Poland
22.13. Qatar
22.14. Russia
22.15. Saudi Arabia
22.16. South Africa
22.17. Spain
22.18. Sweden
22.19. Switzerland
22.20. Turkey
22.21. United Arab Emirates
22.22. United Kingdom
23. Competitive Landscape
23.1. Market Share Analysis, 2024
23.2. FPNV Positioning Matrix, 2024
23.3. Competitive Analysis
23.3.1. Baader Solutions
23.3.2. Biovac
23.3.3. Boehringer Ingelheim Animal Health
23.3.4. Ceva Santé Animale
23.3.5. Elanco Animal Health Incorporated
23.3.6. Hester Biosciences Limited
23.3.7. HIPRA
23.3.8. IDT Biologika
23.3.9. Indian Immunologicals Limited
23.3.10. Merck Animal Health
23.3.11. MSD Animal Health
23.3.12. Phibro Animal Health Corporation
23.3.13. Romvac
23.3.14. VIRBAC Group
23.3.15. Zoetis Inc.
24. ResearchAI
25. ResearchStatistics
26. ResearchContacts
27. ResearchArticles
28. Appendix
List of Figures
FIGURE 1. SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET MULTI-CURRENCY
FIGURE 2. SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2024 VS 2030 (%)
FIGURE 24. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 26. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2024 VS 2030 (%)
FIGURE 28. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 30. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 34. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 40. SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY INACTIVATED WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COMMERCIAL USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PHARMACEUTICAL STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY FARM OWNERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY RUMINANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADVANCED RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TRADITIONAL PRODUCTION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY VIRAL VECTOR-BASED TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADULT SWINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY JUVENILE SWINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PIGLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY NANO-PARTICLE ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY OIL-IN-WATER EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY WATER-IN-OIL EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY LONG-TERM IMMUNITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY SHORT-TERM IMMUNITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY LARGE-SCALE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY MEDIUM-SCALE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY SMALL-SCALE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 93. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 96. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 97. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 100. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 101. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 102. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 104. CANADA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 112. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 113. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 116. MEXICO SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 155. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 158. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 159. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 160. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 162. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 163. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 164. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 165. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 166. CHINA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 167. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 170. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 172. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 175. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 176. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 177. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 178. INDIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 191. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 194. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 195. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 196. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 198. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 199. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 200. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 201. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 202. JAPAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY EFFICACY DURATION, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY AGE GROUP OF TARGET ANIMAL, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY ADJUVANT TYPE, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 261. TAIWAN SWINE EPIDEMIC ENCEPHALITIS INACTIVATED VACCINE MA

Companies Mentioned

  • Baader Solutions
  • Biovac
  • Boehringer Ingelheim Animal Health
  • Ceva Santé Animale
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • HIPRA
  • IDT Biologika
  • Indian Immunologicals Limited
  • Merck Animal Health
  • MSD Animal Health
  • Phibro Animal Health Corporation
  • Romvac
  • VIRBAC Group
  • Zoetis Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Swine Flu Vaccination Market Report 2025 - Product Image

Swine Flu Vaccination Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Porcine Epidemic Diarrhea Vaccines Market Report 2025 - Product Image

Porcine Epidemic Diarrhea Vaccines Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Swine Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Swine Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
U.S. Animal Health Market Size, Share & Trends Analysis Report By Animal Type (Production Animal, Companion Animal), By Product, By Type Of Vaccine, By Disease, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2025 - 2030 - Product Image

U.S. Animal Health Market Size, Share & Trends Analysis Report By Animal Type (Production Animal, Companion Animal), By Product, By Type Of Vaccine, By Disease, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • United States
From
Swine Vaccines Market Size, Share & Trends Analysis Report By Product (Inactivated, Modified/Attenuated Live), By Type (Pseudorabies, Porcine Circovirus Type 2), By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Swine Vaccines Market Size, Share & Trends Analysis Report By Product (Inactivated, Modified/Attenuated Live), By Type (Pseudorabies, Porcine Circovirus Type 2), By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.